Archimedes licenses Oramorph for Germany
This article was originally published in Scrip
The UK firm Archimedes Pharmahas licensed from Molteni Farmaceutici the German rights for Oramorph. Oramorph is the only oral liquid immediate-release morphine sulphate product in patient-friendly unit dose vials available in Germany, and acts quickly to initiate morphine therapy in patients with cancer pain. The product is expected to pave the way for the expected launch of Archimedes’s fentanyl nasal spray, Nasalfent, which is currently in Phase III clinical trials. The German immediate-release morphine market is worth around €17.5 million and is growing at 7% per annum.